Setmelanotide hydrochloride ER is under clinical development by Rhythm Pharmaceuticals and currently in Phase III for Obesity. According to GlobalData, Phase III drugs for Obesity have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Setmelanotide hydrochloride ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Setmelanotide hydrochloride ER overview
Setmelanotide hydrochloride extended release formulation (CAM-4072) is under development for the treatment of genetic obesity including Bardet-Biedl syndrome (BBS). It is administered subcutaneously. The drug candidate is a peptide that acts by targeting the melanocortin 4 receptor (MC4R). it is developed based on FluidCrystal technology. The drug candidate is an extended release formulation.
Rhythm Pharmaceuticals overview
Rhythm Pharmaceuticals is a biopharmaceutical company. It develops and commercializes drugs to treat rare genetic disorders of obesity due to POMC, PCSK1, or LEPR deficiency. The company offers IMCIVREE (setmelanotide), a melanocortin-4 receptor (MC4R) agonist injection for chronic weight management in adults and pediatric patients. The company is advancing RM-853, a ghrelin O-acyltransferase (GOAT) inhibitor targeting Prader-Willi syndrome (PWS). It is also evaluating setmelanotide against bardet-biedl syndrome. The company offers its products in Israel, China, Hong Kong and Macau. Rhythm Pharma is headquartered in Boston, Massachusetts, the US.
For a complete picture of Setmelanotide hydrochloride ER’s drug-specific PTSR and LoA scores, buy the report here.